Trials / Withdrawn
WithdrawnNCT01423539
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bendamustine | Intravenous repeating dose\\n |
| DRUG | navitoclax | Oral repeating dose\\n |
| DRUG | rituximab | Intravenous repeating dose\\n |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2011-08-26
- Last updated
- 2016-11-02
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01423539. Inclusion in this directory is not an endorsement.